Edwards Lifesciences Corporation

NYSE:EW Voorraadrapport

Marktkapitalisatie: US$39.5b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Edwards Lifesciences Toekomstige groei

Future criteriumcontroles 1/6

Edwards Lifesciences zal naar verwachting groeien in winst en omzet met respectievelijk 5.1% en 4.6% per jaar. De winst per aandeel zal naar verwachting groeien met 5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 16.2% zijn.

Belangrijke informatie

5.8%

Groei van de winst

5.0%

Groei van de winst per aandeel

Medical Equipment winstgroei17.5%
Inkomstengroei4.6%
Toekomstig rendement op eigen vermogen16.2%
Dekking van analisten

Good

Laatst bijgewerkt04 Oct 2024

Recente toekomstige groei-updates

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Feb 08
Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Recent updates

Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates

Sep 11
Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Aug 30
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Aug 17
Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut

Jul 26

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Jul 26
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E

Jul 12
Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Jun 24
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Edwards Lifesciences Corp Looks Bullish (Technical Analysis)

Jun 22

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

May 13
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)

May 09

When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?

Apr 29
When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Apr 15
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear

Apr 01
Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear

Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture

Feb 21
Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture

Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)

Feb 14

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Feb 08
Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly

Jan 28
Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly

The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing

Jan 14
The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing

Edwards Lifesciences: Undervalued With A Substantial Upside Potential

Jan 09

Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up

Dec 31
Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up

Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Dec 17
Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets

Oct 26

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Oct 23
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Oct 09
Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Sep 26
Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Sep 11
A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences: Rising Dominance In Structural Heart Disease

Aug 21

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Jul 16
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?

Jun 30
Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Jun 15
Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Edwards Lifesciences: Valuation Premium Earned, But Shares Are Not Cheap, Technicals Mixed

Jun 12

Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?

May 31
Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?

Winst- en omzetgroeiprognoses

NYSE:EW - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20266,5901,7111,5841,87517
12/31/20255,9941,5701,5991,87921
12/31/20245,9511,3891,7672,0739
6/30/20246,2041,540552866N/A
3/31/20246,1141,428251528N/A
12/31/20236,0051,402630896N/A
9/30/20235,3621,3417751,042N/A
6/30/20235,2011,300669940N/A
3/31/20235,2791,4519721,239N/A
12/31/20225,3821,5229531,218N/A
9/30/20225,3641,4591,0401,309N/A
6/30/20225,3551,4551,2611,531N/A
3/31/20225,3571,5391,4281,725N/A
12/31/20215,2331,5031,4021,732N/A
9/30/20215,0951,4771,4091,758N/A
6/30/20214,9251,4621,0501,443N/A
3/31/20214,4748517171,148N/A
12/31/20204,3868236471,054N/A
9/30/20204,3697946921,057N/A
6/30/20204,3227449411,279N/A
3/31/20204,4841,1081,0871,389N/A
12/31/20194,3481,0479051,183N/A
9/30/20194,1527748091,073N/A
6/30/20193,964725705978N/A
3/31/20193,821765523777N/A
12/31/20183,723722685927N/A
9/30/20183,634712754998N/A
6/30/20183,549657772966N/A
3/31/20183,447560N/A1,024N/A
12/31/20173,435584N/A1,001N/A
9/30/20173,315745N/A838N/A
6/30/20173,232716N/A733N/A
3/31/20173,150657N/A726N/A
12/31/20162,964570N/A704N/A
9/30/20162,867552N/A607N/A
6/30/20162,743528N/A604N/A
3/31/20162,601515N/A584N/A
12/31/20152,494495N/A550N/A
9/30/20152,441463N/A539N/A
6/30/20152,433440N/A349N/A
3/31/20152,391874N/A957N/A
12/31/20142,323811N/A1,022N/A
9/30/20142,241777N/A1,040N/A
6/30/20142,129759N/A1,160N/A
3/31/20142,071306N/A511N/A
12/31/20132,046389N/A473N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei EW ( 5.1% per jaar) ligt boven de spaarquote ( 2.5% ).

Winst versus markt: De winst van EW ( 5.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.2% per jaar).

Hoge groeiwinsten: De winst van EW zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van EW ( 4.6% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van EW ( 4.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen EW zal naar verwachting over 3 jaar laag zijn ( 16.2 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y